vs
Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $908.9K, roughly 1.5× T Stamp Inc). On growth, FATE THERAPEUTICS INC posted the faster year-over-year revenue change (-26.4% vs -39.3%). T Stamp Inc produced more free cash flow last quarter ($2.0M vs $-112.0M). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -15.7%).
Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
FATE vs IDAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $908.9K |
| Net Profit | — | $-2.5M |
| Gross Margin | — | — |
| Operating Margin | — | -224.9% |
| Net Margin | — | -279.9% |
| Revenue YoY | -26.4% | -39.3% |
| Net Profit YoY | 37.9% | 57.7% |
| EPS (diluted) | — | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4M | $908.9K | ||
| Q3 25 | $1.7M | $872.5K | ||
| Q2 25 | $1.9M | $812.7K | ||
| Q1 25 | $1.6M | $545.5K | ||
| Q4 24 | $1.9M | $1.5M | ||
| Q3 24 | $3.1M | $511.1K | ||
| Q2 24 | $6.8M | $500.4K | ||
| Q1 24 | $1.9M | $573.7K |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-32.3M | $-1.9M | ||
| Q2 25 | $-34.1M | $-1.7M | ||
| Q1 25 | $-37.6M | $-2.2M | ||
| Q4 24 | — | $-6.0M | ||
| Q3 24 | $-47.7M | $-1.3M | ||
| Q2 24 | $-38.4M | $-2.6M | ||
| Q1 24 | $-48.0M | $-2.7M |
| Q4 25 | — | -224.9% | ||
| Q3 25 | -1995.1% | -203.0% | ||
| Q2 25 | -1938.5% | -207.0% | ||
| Q1 25 | -2534.1% | -396.5% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | -1703.9% | -523.7% | ||
| Q2 24 | -665.7% | -524.7% | ||
| Q1 24 | -2652.9% | -496.7% |
| Q4 25 | — | -279.9% | ||
| Q3 25 | -1852.4% | -219.1% | ||
| Q2 25 | -1786.6% | -210.7% | ||
| Q1 25 | -2309.5% | -395.5% | ||
| Q4 24 | — | -401.5% | ||
| Q3 24 | -1551.0% | -245.7% | ||
| Q2 24 | -567.4% | -519.3% | ||
| Q1 24 | -2493.7% | -466.9% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-0.27 | $-0.72 | ||
| Q2 25 | $-0.29 | $-0.69 | ||
| Q1 25 | $-0.32 | $-0.89 | ||
| Q4 24 | — | $-3.14 | ||
| Q3 24 | $-0.40 | $-1.06 | ||
| Q2 24 | $-0.33 | $-3.19 | ||
| Q1 24 | $-0.47 | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.7M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $207.2M | $8.7M |
| Total Assets | $318.9M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.7M | $6.0M | ||
| Q3 25 | $215.4M | $5.4M | ||
| Q2 25 | $222.8M | $292.1K | ||
| Q1 25 | $240.4M | $1.1M | ||
| Q4 24 | $279.1M | $2.8M | ||
| Q3 24 | $296.9M | $598.0K | ||
| Q2 24 | $304.9M | $659.5K | ||
| Q1 24 | $121.3M | $816.7K |
| Q4 25 | $207.2M | $8.7M | ||
| Q3 25 | $234.1M | $6.1M | ||
| Q2 25 | $261.4M | $2.4M | ||
| Q1 25 | $288.4M | $4.1M | ||
| Q4 24 | $318.7M | $3.0M | ||
| Q3 24 | $362.3M | $5.4M | ||
| Q2 24 | $397.0M | $750.4K | ||
| Q1 24 | $426.1M | $1.4M |
| Q4 25 | $318.9M | $11.2M | ||
| Q3 25 | $343.7M | $11.2M | ||
| Q2 25 | $371.6M | $5.7M | ||
| Q1 25 | $398.7M | $6.6M | ||
| Q4 24 | $440.7M | $8.6M | ||
| Q3 24 | $495.0M | $10.6M | ||
| Q2 24 | $528.8M | $5.2M | ||
| Q1 24 | $569.9M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-106.1M | $2.0M |
| Free Cash FlowOCF − Capex | $-112.0M | $2.0M |
| FCF MarginFCF / Revenue | -8183.9% | 215.4% |
| Capex IntensityCapex / Revenue | 434.8% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-199.6M | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-106.1M | $2.0M | ||
| Q3 25 | $-24.4M | $-4.0M | ||
| Q2 25 | $-24.6M | $-2.1M | ||
| Q1 25 | $-33.8M | $-1.5M | ||
| Q4 24 | $-122.9M | $-2.7M | ||
| Q3 24 | $-29.4M | $-2.4M | ||
| Q2 24 | $-32.3M | $-1.6M | ||
| Q1 24 | $-33.4M | $-2.2M |
| Q4 25 | $-112.0M | $2.0M | ||
| Q3 25 | $-26.6M | $-4.0M | ||
| Q2 25 | $-25.9M | $-2.1M | ||
| Q1 25 | $-35.0M | $-1.6M | ||
| Q4 24 | $-123.6M | $-2.7M | ||
| Q3 24 | $-29.9M | $-2.4M | ||
| Q2 24 | $-32.4M | $-1.6M | ||
| Q1 24 | $-33.4M | $-2.2M |
| Q4 25 | -8183.9% | 215.4% | ||
| Q3 25 | -1526.5% | -459.6% | ||
| Q2 25 | -1360.7% | -258.6% | ||
| Q1 25 | -2148.9% | -289.2% | ||
| Q4 24 | -6645.4% | -182.9% | ||
| Q3 24 | -973.1% | -475.4% | ||
| Q2 24 | -477.8% | -320.9% | ||
| Q1 24 | -1736.9% | -376.6% |
| Q4 25 | 434.8% | 0.8% | ||
| Q3 25 | 126.5% | 0.0% | ||
| Q2 25 | 71.4% | 0.2% | ||
| Q1 25 | 73.4% | 6.8% | ||
| Q4 24 | 39.2% | 0.1% | ||
| Q3 24 | 16.1% | 0.7% | ||
| Q2 24 | 0.8% | 1.3% | ||
| Q1 24 | 4.5% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
